Advanced

Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes

Wisloff, F; Gulbrandsen, N; Hjorth, M; Lenhoff, Stig LU and Fayers, P (2005) In European Journal of Haematology 75(4). p.293-298
Abstract
Earlier studies showing a negative impact of anaemia on quality of life (QOL) lack adequate adjustment for confounding factors such as disease stage and tumour response. We examined the impact of haemoglobin concentration on QOL scores of 745 multiple myeloma patients followed from diagnosis, adjusting for objective disease parameters. Data from two Nordic studies with the EORTC QLQ-C30 questionnaire were analysed using linear regression analysis. Haemoglobin was independently related only to fatigue at baseline (P = 0.001) and at 12 months (P = 0.010). In multivariate analysis, extent of skeletal disease was at least as strong a predictor for fatigue at diagnosis as haemoglobin and was also related to other important QOL scores such as... (More)
Earlier studies showing a negative impact of anaemia on quality of life (QOL) lack adequate adjustment for confounding factors such as disease stage and tumour response. We examined the impact of haemoglobin concentration on QOL scores of 745 multiple myeloma patients followed from diagnosis, adjusting for objective disease parameters. Data from two Nordic studies with the EORTC QLQ-C30 questionnaire were analysed using linear regression analysis. Haemoglobin was independently related only to fatigue at baseline (P = 0.001) and at 12 months (P = 0.010). In multivariate analysis, extent of skeletal disease was at least as strong a predictor for fatigue at diagnosis as haemoglobin and was also related to other important QOL scores such as physical functioning, role functioning, global QOL and pain (P < 0.001). At 12 months' follow-up, response to therapy was related to physical functioning (P < 0.001) and pain (P = 0.001). In conclusion, haemoglobin and extent of skeletal disease were both predictors for fatigue in patients with newly diagnosed multiple myeloma, but extent Of skeletal disease was also associated with other important QOL scores. During follow-up, response to therapy emerged as an important predictor variable. When examining the effect of haemoglobin on QOL, it is essential to adjust for disease parameters and response to therapy in order not to overestimate the impact of haemoglobin on QOL. Our findings imply that uncontrolled studies on the effect of erythropoietin (EPO) in cancer patients may be making exaggerated claims for the effect of EPO on QOL. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
disease parameters, myeloma, quality of life, haemoglobin, regression, multiple
in
European Journal of Haematology
volume
75
issue
4
pages
293 - 298
publisher
Wiley-Blackwell
external identifiers
  • wos:000231907000004
  • pmid:16146535
  • scopus:24744446425
ISSN
1600-0609
DOI
10.1111/j.1600-0609.2005.00509.x
language
English
LU publication?
yes
id
0ba29765-79ec-42fc-95a1-3ce8094214d4 (old id 224534)
date added to LUP
2007-08-23 11:29:27
date last changed
2017-01-01 04:50:15
@article{0ba29765-79ec-42fc-95a1-3ce8094214d4,
  abstract     = {Earlier studies showing a negative impact of anaemia on quality of life (QOL) lack adequate adjustment for confounding factors such as disease stage and tumour response. We examined the impact of haemoglobin concentration on QOL scores of 745 multiple myeloma patients followed from diagnosis, adjusting for objective disease parameters. Data from two Nordic studies with the EORTC QLQ-C30 questionnaire were analysed using linear regression analysis. Haemoglobin was independently related only to fatigue at baseline (P = 0.001) and at 12 months (P = 0.010). In multivariate analysis, extent of skeletal disease was at least as strong a predictor for fatigue at diagnosis as haemoglobin and was also related to other important QOL scores such as physical functioning, role functioning, global QOL and pain (P &lt; 0.001). At 12 months' follow-up, response to therapy was related to physical functioning (P &lt; 0.001) and pain (P = 0.001). In conclusion, haemoglobin and extent of skeletal disease were both predictors for fatigue in patients with newly diagnosed multiple myeloma, but extent Of skeletal disease was also associated with other important QOL scores. During follow-up, response to therapy emerged as an important predictor variable. When examining the effect of haemoglobin on QOL, it is essential to adjust for disease parameters and response to therapy in order not to overestimate the impact of haemoglobin on QOL. Our findings imply that uncontrolled studies on the effect of erythropoietin (EPO) in cancer patients may be making exaggerated claims for the effect of EPO on QOL.},
  author       = {Wisloff, F and Gulbrandsen, N and Hjorth, M and Lenhoff, Stig and Fayers, P},
  issn         = {1600-0609},
  keyword      = {disease parameters,myeloma,quality of life,haemoglobin,regression,multiple},
  language     = {eng},
  number       = {4},
  pages        = {293--298},
  publisher    = {Wiley-Blackwell},
  series       = {European Journal of Haematology},
  title        = {Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes},
  url          = {http://dx.doi.org/10.1111/j.1600-0609.2005.00509.x},
  volume       = {75},
  year         = {2005},
}